The 3 new senior leaders, Dr. Gudkov, Dr. Adjei, and Mr. Walker, bring fresh ideas and perspectives to theInstitute as well as a wealth of scientific program development, and administrative leadership experiencegarnered from their involvement at other major NCI-designated cancer programs (Case ComprehensiveCancer Center, Mayo Clinic Cancer Center and the Ohio State University Comprehensive Cancer Center,respectively).Each of the Senior Leaders also plays a pivotal role in a CCSG Programs or Shared Resources. Dr. Adjeiserves as Leader of the Molecular Targets and Experimental Therapeutics (MTET) and oversees ClinicalResearch Services, Dr. Gudkov is Leader of the Cell Stress and Biophysical Therapies (CSBT) Program, andDr. James Marshall leads the Cancer Prevention and Population Sciences (CPPS) program. Dr. CandaceJohnson is an active participant in the Prostate Program and MTET, while Dr. Trump participates in theMolecular Targets and Experimental Therapeutics Program. Mr. Walker serves as the CCSG Administratorand oversees the CCSG shared resources. All members of the Senior Leadership Team are active in thefaculty recruitment process, serving as chairs or members of search committees. Further they are alsoinvolved in coordinating the EAB meetings, annual retreats, symposia/seminar series and participating indevelopment activities. Each of these leaders is also active in national cancer research forums and wellintegrated into leadership and committee positions in these external arenas (ASCO, AACR, AACI, NCCN, NCI[caBIG, IRGs, parent committees]) assuring their awareness of and participation in deliberations regardingimportant national topics in cancer research, care and education and guaranteeing RPCI awareness of andleadership in the national trends.The Senior Leadership team interacts informally on a daily basis and meets formally on a weekly basis in theprimary administrative leadership forum known as the RPCI Executive Council. Chaired by Dr. Trump, theExecutive Council is the major decision-making body of the Institute, responsible for the on-going oversight ofthe RPCI and addressing all functional issues raised by its members. In addition, the Senior Leadershipparticipates on the CCSG Steering Committee, a committee that meets monthly and includes the researchprogram leaders as well as leaders of important CCSG and Institute initiatives [e.g., Imaging Development,Health Disparities]. The CCSG Steering Committee, chaired by Dr. Trump, provides a venue for strategicplanning, program evaluation, membership review and approval and review of existing and proposed sharedresources. Although there are several other venues where the Senior Leadership participates, it is throughthese two committees that primary decision-making is accomplished.There has been dramatic growth in RPCI during the last funding cycle. Over this funding cycle (2002 to 2006)the Senior Leadership team worked together to recruit more than 100 cancer investigators and clinicians,increase NCI funding by 74%, increase accruals to therapeutic investigator-initiated clinical trials and increasein out patient volume by 42% over this time period. As the number of cancer-focused basic, translational,clinical and population investigators at the RPCI have grown, four new Shared Resources have beenestablished to support the needs of the membership with three more now in development. It is anticipated thatthe current Senior Leadership team will continue this successful trajectory via developing and executing longtermvision and strategic planning for the Institute.
Showing the most recent 10 out of 1555 publications
